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Abstract
The life altering nature of major limb amputations may be further complicated by neuroma formation in up to 60% of the
estimated 2 million major limb amputees in the United States. This can be a source of pain and functional limitation of the
residual limb. Pain associated with neuromas may limit prosthetic limb use, require reoperation, lead to opioid dependence,
and dramatically reduce quality of life. A number of management options have been described including excision alone,
excision with repair, excision with transposition, and targeted muscle reinnervation. Targeted muscle reinnervation has been
shown to reduce phantom limb and neuroma pain for patients with upper and lower extremity amputations. It may be
performed at the time of initial amputation to prevent pain development or secondarily for the treatment of established pain.
Encouraging outcomes have been reported, and targeted muscle reinnervation is emerging as a leading surgical technique for
pain prevention in patients undergoing major limb amputations and pain management in patients with pre-existing amputations.
Keywords
Neuroma, pain, TMR, amputation, neuroma, nerve transfer, nerve, chronic pain, residual limb pain, stump pain, phantom
limb pain
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Background
Major limb amputations are life altering events for patients.
Beyond the deficits in form and function, there is a risk of
significant post-amputation pain that can manifest itself in
the weeks, months, and years following the amputation. This
pain decreases quality of life, increases the risk of depression, negatively affects interpersonal relationships, and
impacts the ability to return to work.1 It has been reported
that 70%–80% of the greater than 2 million major limb
amputees in the United States deal with chronic pain of varying etiologies.1,2 The commonly reported amputation-related
pain etiologies can be categorized as residual limb pain
(RLP), phantom limb pain (PLP), and neuroma pain.
RLP, commonly referred to as “stump pain,” is localized
intense pain that impacts prosthetic use and is a frequent
cause of revision surgery.3 There are several etiologies of
RLP including organic causes such as soft tissue inflammation, infection, osteomyelitis, and heterotopic ossification,
but symptomatic neuromas are most often the underlying

cause. It is important to differentiate the etiology of RLP
when recommending management. The mechanisms of
PLP, or the perceived notion of pain in the amputated limb,
are not entirely understood. However, both PLP and neuroma-related RLP are related to the transection of major
nerves—a necessary step of any amputation. When a peripheral nerve is severed, it will invariably attempt to regenerate. Nerve regeneration is guided both by the intrinsic
pathway in the nerve and by signals from the distal target
that it innervates. When these distal targets are unavailable,
as is the case with a major limb amputation, there is a greater
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risk of aberrant and inappropriate axonal regeneration leading to the formation of amputation site neuromas.
A neuroma consists of uncontrolled axonal growth
entwined with myofibroblasts, Schwann cells, and endothelial cells. Up to 60% of patients with a nerve injury can
develop a painful neuroma.4,5 Traditional amputation techniques addressed major nerves with traction neurectomy at
the time of limb amputation. In this technique, traction is
applied to the nerve as it is transected as proximal as possible
so that the severed end will retract under viable proximal soft
tissue. Despite traction neurectomy being a standard part of
amputation technique, amputation site pain and neuroma formation are still a significant problem that impact overall
quality of life after limb amputation.
The scope of this issue should not be underestimated.
There are approximately 185,000 major limb amputations
performed each year and approximately 2 million amputees
currently living in the United States.6 This population is projected to rise to 3.6 million by 2050.7 Phantom limb pain and
RLP following major amputations are unfortunately quite
common, with a prevalence of at least 30%–50%.8 These
numbers are likely under reported. Following major limb
amputations, there is a 40%–50% reoperation rate, with neuromas being the second most common reason for
reoperation.9,10Beyond the pain itself, neuromas often make
the use of a prosthetic uncomfortable or intolerable, which
impacts the functional quality of a patient’s life.6
As our understanding of the peripheral nervous system
has improved, it has become clear that severed nerves will
invariably attempt to regenerate from the site of neurectomy
to reach a distal target.11 In the case of traditional amputation, no distal target is available, leaving a high risk situation
for neuroma formation. This can have significant consequences for both the peripheral and the central nervous systems, as patients can theoretically eventually develop
centralization of their pain symptoms.6 Management of neuroma-associated pain is multifactorial. There can be several
contributing factors including mechanical pain, centralized
pain, depression and psychosocial issues. Surgical intervention addresses the mechanical aspect of a patient’s pain.
With the substantial morbidity seen following major limb
amputations secondary to neuroma pain, strategies are
needed to both prevent and treat neuromas. Over 100 surgical techniques have been reported for the surgical treatment
of neuromas, with no consensus on the best treatment. A
comparative meta-analysis stratified patients into 5 groups
according to the treatment they received: excision and transposition (63%), excision only (35%), excision and repair
(20%), neurolysis and coverage (19%), and excision and cap
(4%).12 This study concluded that surgical treatment resulted
in a meaningful reduction in pain in 77% of the patients with
no significant differences between surgical techniques. In
stratified analysis for confounding variables, excision and
transposition and neurolysis with coverage were statistically
more effective when neuroma pain was present for greater
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than 24 months prior to surgery or when the patient had
already had one or more prior operations compared to excision and repair or excision alone, respectively.12 These findings suggest that surgery can be an effective intervention for
the management of neuroma pain. However, there remains
much room for improvement.

Clinical and anatomic applications of
targeted muscle reinnervation
Targeted muscle reinnervation (TMR) offers a new approach
to neuroma management—as a result a paradigm shift regarding the surgical management of neuromas is currently taking
place. It has been known for decades that placing a severed
nerve end into muscle capitalizes on our understanding that
microenvironment matters for nerve regeneration.13Placement
of transected sensory nerves in muscle yields small, organized nerve fibers with no myofibroblasts, neuroma formation,
or connections to the skin.13In TMR, this is taken a step further and the severed nerves are coapted to end motor targets
(the entry point of a nerve branch into muscle) of an innervated muscle, giving the severed nerves analogous tissue and
a functional target to reinnervate. In other words, TMR gives
the regenerating fascicles “somewhere to go and something
to do,” not just “somewhere to go.”14 TMR that is performed
months to years after the index amputation surgery, when the
patient has established neuroma pain, is referred to as “secondary” TMR. The successful clinical results seen with secondary TMR led to the development of “primary” TMR,
performed at the time of limb amputation, in an effort to prevent development of PLP and neuroma pain. The objectives
of primary TMR are the prevention of symptomatic neuromas
and PLP, while the objective of secondary TMR is the treatment of symptomatic neuroma and PLP.

TMR in the upper limb
Introduced clinically in 2004, TMR was originally designed
to improve prosthetic function after upper extremity amputation by innervating residual muscles to create additional
electromyographic signals to operate a myoelectric prosthesis.15 Substantial clinical success was demonstrated with
several initial case reports.16–18Notably, the amplification of
myoelectric signals for advanced bioprosthetic limbs in the
upper extremity occurs regardless of the timing of TMR, that
is, whether it is performed as primary or secondary TMR.18
In addition to good functional outcomes, it was noted that
many patients who underwent TMR had subjective improvement in their pain.18 This led to studies investigating TMR as
a clinical strategy to treat established neuromas of amputated
limbs. TMR in the upper limb is now commonly employed
to optimize control of myoelectric prostheses, but is also utilized for prevention or treatment of neuroma pain.19–23
Among patients with upper limb amputations, those with
transradial amputations are most likely to report phantom
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pain and the use of neuropathic pain medication.24 The specific nerve transfers for TMR in the upper limb may vary
depending on the exact level of amputation and quality of the
remaining soft tissue.21,25 In the initial description of TMR
for shoulder disarticulation, a cadaveric dissection demonstrated that the median, musculocutaneous, radial, and ulnar
nerves could be identified several centimeters proximal to
the glenohumeral joint.15 In addition, these nerves were able
to reach the pectoralis motor targets (where the respective
pectoral nerve branches are entering the muscle), and the
segmental innervation of the pectoralis major proved to be
favorable for TMR.15

TMR in the Lower Limb
TMR of the lower extremity is often performed in below
knee and above knee amputations and is used to prevent or
treat neuroma and PLP.18 Current mainstream lower extremity prosthetics do not require the myoelectric signals that
their upper extremity counterparts do. Thus, performing
TMR in the lower extremity, whether it be primary or secondary, is typically aiming to prevent and treat neuroma formation and pain only.
An anatomic dissection series was recently performed to
identify a roadmap for the identification of end motor targets
for TMR in a below knee amputation.26 In this study, the
major branch points of motor nerves and the motor entry
points to the muscles of the leg were dissected in five cadaver
specimens. This dissection series demonstrated that the tibialis anterior and the extensor digitorum longus were both
acceptable targets in the anterior compartment. The peroneus
longus had the most optimal motor entry points in the lateral
compartment. In the superficial posterior compartment, the
gastrocnemius and soleus muscles were both acceptable targets. The flexor digitorum longus was considered the best
target located in the deep posterior compartment of the lower
leg. This study provided a helpful road map to locate motor
entry points in which to perform TMR in the lower extremity
and aid in intra-operative decision making.26
A similar anatomic dissection series was performed to
identify motor targets in the setting of a transfemoral (“aboveknee”) amputation.27 Five lower limbs were dissected and the
motor points of the 13 muscles of the thigh were assessed. At
this level, the tibial and the common peroneal nerves are the
main nerves to be transferred into motor end points of nearby
muscles for TMR. In this dissection series, the motor points
to the biceps femoris and the semimembranosus were found
to be the most easily coapted to the common peroneal and
tibial nerves, respectively. The motor end points were in close
proximity to these nerves and consistently located over a
smaller territory along the thigh. The gracilis, adductor longus, vastus lateralis and vastus intermedius were considered
as alternative motor endpoints based on their proximity to the
tibial and common peroneal nerves, but have more widespread motor end point distributions. The other muscles of
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the thigh, notably the rectus femoris, sartorius, vastus medialis, adductor brevis and adductor magnus muscles had motor
points removed from the tibial and the common peroneal
nerves that would necessitate a more difficult nerve coaptation. Therefore, these motor points are less ideal for TMR in
a transfemoral amputation.27

Surgical technique
The amputation is performed per the surgeon’s preferred
technique, accounting for soft tissue needs. Note that for secondary TMR cases, marking the site of any Tinel signs preoperatively may help to locate neuromas.21If the amputation
is performed under tourniquet control, nerve stimulation to
identify end motor targets should be performed within 20–
30 min for reliable stimulation. Otherwise, the tourniquet
must be released both for the purpose of hemostasis as well
as allowing sufficient time for the nerves to recover from the
ischemic palsy for stimulation. The use of a hand-held nerve
stimulator allows identification of motor nerve branches
entering the target muscle, known as the “end motor targets.”
When performing TMR, paralytic agents and nerve blocks
should be avoided until the nerve transfers are completed.
The major peripheral nerves are identified and transected,
leaving a substantial length to later perform TMR.
Significantly more length needs to be left on the proximal
nerves compared to a traditional amputation as the length is
needed to facilitate the nerve transfer component of TMR.
End motor targets are identified on neighboring innervated
yet now de-functioned muscles. Ideal muscles for TMR are
those that have lost their insertion sites as part of the amputation procedure (“defunctioned”) or have function that is
redundant and have a motor innervation point that is in close
proximity to the donor nerve.22,25The major peripheral nerves
that were previously transected are then coapted to the
defunctioned muscle just proximal to the entry point of the
motor branch into the muscle. End-to-end coaptation is performed from the transected peripheral nerve stump to the
recipient motor nerve branch, typically using 8-0 nylon
epineurial sutures. Fibrin glue may be utilized to augment
the nerve coaptation as well.25 If there is significant size discrepancy, muscle surrounding the motor nerve recipient is
dissected to create a cuff of muscle tissue around the nerve
coaptation with 5-0 suture. This theoretically optimizes
ingrowth of the nerve transfer into both the target motor
nerve as well as directly neurotizing the muscle. Different
combinations of nerve transfer have been described, but any
combination of nerve transfers will provide the amputated
nerve with a target muscle. This is uniformly how TMR is
approached, and the technique can be applied at almost any
level of amputation. Recent reports have even described this
technique in digital amputation.28
For transradial amputations, TMR is typically performed
for the median, ulnar and radial nerves. Common nerve transfers for transradial amputation TMR are listed in Table 1. At
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Table 1. Recipient motor branches frequently utilized for targeted muscle reinnervation for each major nerve of the upper extremity
by amputation level.
Donor nerve
Transradial amputations
Median nerve
Ulnar nerve
Superficial radial nerve
Transhumeral amputations
Median nerve
Ulnar nerve
Radial nerve
Shoulder disarticulation
Musculocutaneous nerve
Median nerve
Ulnar nerve
Radial nerve

Recipient motor nerve branches
Flexor digitorum superficialis, flexor digitorum profundus, brachioradialis, extensor
carpi radialis longus, flexor capri radialis, palmaris longus
Flexor carpi ulnaris, flexor pollicis longus, extensor carpi radialis brevis, palmaris longus
Flexor digitorum profundus
Short head of biceps
Brachialis
Lateral head of the triceps
Clavicular head of pectoralis major
Segment of sternal head of pectoralis major
Segment of sternal head of pectoralis major
Thoracodorsal nerve

performed for TMR in below knee amputations are summarized in Table 2.29 In transfemoral amputations, TMR is usually performed for the tibial and common peroneal nerves.
The posterior femoral cutaneous nerve may be coapted endto-side to the tibial nerve for sensory reinnervation, if
desired.4The common nerve transfers performed for TMR in
transfemoral amputations (Figure 2) are also summarized in
Table 2.

Outcomes

Figure 1. Intra-operative photo demonstrating the saphenous,
sural, tibial, deep peroneal (DPN), and superficial peroneal (SPN)
nerves in a below knee amputation prior to targeted muscle
reinnervation.

the transhumeral level, TMR is usually performed for the
musculocutaneous, median, ulnar and radial nerves (Table 1).
For shoulder disarticulations, or very proximal transhumeral
amputations, the infraclavicular brachial plexus is exposed.21
The cords of the brachial plexus can also be identified at this
level. The specific nerve coaptations performed may vary at
this level; see Table 1.
In below knee amputations, TMR is typically performed
for the saphenous, sural, superficial and deep peroneal and
the tibial nerves (Figure 1).29 The common nerve transfers

Since its inception, the literature continues to demonstrate
reliable improvement in outcomes with TMR related to both
pain and function for patients requiring amputation. Souza
et al.19 retrospectively evaluated the effect of TMR on residual neuroma pain in upper-extremity amputees. The primary
purpose for TMR in this case series was improved myoelectric control for shoulder disarticulations and transhumeral
amputations. Of the 26 patients in this study, 15 had evidence
of postamputation neuroma pain before undergoing TMR.
Of these 15 patients with neuroma pain, 14 had complete
resolution, and one patient had improvement, but not complete resolution, of pain. The other 11 patients did not have
any evidence of postamputation neuroma pain and remained
free of neuroma pain after the procedure.19 A recent randomized control trial assessed the effect of TMR on 28 amputees with established neuroma pain who were assigned
randomly to standard treatment with traction neurectomy or
TMR.14 This study demonstrated a trend toward reduced
RLP in the TMR group. Phantom limb pain scores were significantly better in the TMR group compared to traction neurectomy group. Results from this study also suggested that
earlier (i.e. primary) TMR may be more effective in the prevention and treatment of neuropathic pain.14
Valerio et al.30 performed a multi-institutional cohort
study to assess the preemptive treatment of PLP and RLP
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Table 2. Recipient motor branches frequently utilized for targeted muscle reinnervation for each major nerve of the lower extremity
by amputation level.
Donor nerve
Below knee amputations
Posterior tibial nerve
Deep peroneal nerve
Superficial peroneal nerve
Saphenous nerve
Sural nerve
Transfemoral amputations
Common peroneal nerve
Tibial nerve
Posterior femoral cutaneous nerve

Recipient motor nerve branches
Medial or lateral gastrocnemius, tibialis posterior, medial or lateral soleus
Tibialis anterior, peroneus longus or peroneus brevis, medial soleus
Peroneus longus or peroneus brevis
Medial gastrocnemius, medial soleus or vastus medialis
Tibialis posterior or soleus
Biceps femoris
Semimembranosis
Tibial nerve (end to side)

authors of this study recommended strong consideration of
primary TMR to reduce pathologic PLP and symptomatic
neuroma-related RLP.30
Bowen and colleagues performed TMR on 22 below knee
amputations: 18 primary and 4 secondary amputations.29 No
patients developed symptomatic neuromas during the average follow up period of 18 months. In regard to PLP, 72% of
patients in the primary amputation group experienced PLP in
the first month, with an abrupt decline to 19% 3 months postoperatively and 13% at 6 months. These rates of neuroma
pain and PLP represented substantial improvement over the
control rates at their institution with traditional amputation.29

Discussion

Figure 2. This patient with an above knee amputation is
positioned prone for secondary targeted muscle reinnervation.
The sciatic nerve will be divided into the tibial and common
peroneal divisions and coapted to the nerves to the
semimembranosus (SM) and biceps femoris (BF), respectively.

with TMR at the time of major limb amputation. Fifty-one
patients undergoing immediate TMR were compared with
438 unselected major limb amputees. This cohort study demonstrated lower rates of PLP in the TMR group compared to
the control group. Patient-Reported Outcomes Measurement
Information System (PROMIS) scores were lower in the
TMR group for PLP, pain behavior, pain interference and
RLP. There were significant improvements in numerical rating scale pain scores as well. The TMR group also demonstrated a reduction in the use of opioid medications. The

TMR is still a relatively new area of peripheral nerve surgery, and many questions remain. The ideal time interval as
well as the differences in outcomes of primary versus secondary TMR still need to be further elucidated. As the procedure requires microsurgical nerve coaptation, it is often
performed by a peripheral nerve surgeon. This may limit the
applicability as a primary technique in many centers, due to
the overall paucity of peripheral nerve surgeons. The exact
groups of patients that will benefit most from the procedure
also needs to be better defined. Although, it is highly possible that all patients would benefit from TMR, factors such as
patient age and amputation level may come into play.
Recently, a hind limb amputation model in rats has been
developed for further study of neuroma prevention with
TMR; in addition to an earlier study looking at the effects of
TMR on neuromas in a rabbit rectus abdominis flap
model.31,32 These models may serve as the basis for future
clinical studies.
Alternative techniques for the management of neuroma
pain in amputees have also been described, including regenerative peripheral nerve interface (RPNI).33 RPNI uses free
muscle grafts as physiologic targets. A series of patients
treated with RPNI for post-amputation neuroma pain included
46 RPNIs in 16 patients. At 7.5-month follow-up, there was a
71% reduction in neuroma pain and 53% reduction in PLP.33
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There are similarities between TMR and RPNI, such as
allowing for nerve regeneration into a functional target and
creating a good environment for the nerve ending with coverage of the nerve end with muscle and stable soft tissue.
However, further studies are needed to compare outcomes of
TMR and how they relate to outcomes of RPNI. The use of
acellular nerve allografts (ANA) as a cap to limit axon regeneration has also been investigated for the management of neuroma pain.34 Proof of concept was established in a rat model
demonstrating that ANAs attached to the proximal end of an
injured nerve limited axon growth in a controlled matter,
resulting in a lack of neuroma formation. In addition, the
extent of axon growth from the injured nerve into the ANA
was dependent on the ANA length.34 Clinically, this would
allow the surgeon to reliably terminate the axonal regeneration from an injured nerve by selecting an appropriate length
ANA. This provides a less technically challenging, but more
costly option for neuroma management. However, this technique differs markedly from TMR and RPNI as it does not
provide functional nerve receptors or motor targets.
There are several limitations to this review. Overall, TMR
is still a very new technique—in its infancy stage. Therefore,
there is only a small number of studies to draw conclusions
from, mostly out of 1-2 centers that have the bulk of the
experience with this technique. There is a need for further
high level research and randomized controlled trials in this
field. Currently, there is only one randomized clinical trial
1(RCT) comparing TMR to the standard treatment of neuroma excision and burying into muscle.14 In addition, many
specialties at virtually every major surgical center perform
major limb amputation. Due to the scale of practice change
that would occur with recommending TMR at the time of
each primary limb amputation, there is a need for consistent
high level evidence to support this practice. Further elucidating any differences in pain outcomes between the upper and
lower extremities may also help answer the question of the
role of primary TMR, as significantly more lower extremity
amputations are performed compared to amputations in the
upper extremity. Early studies seem to report higher percentages of pain free patients undergoing upper extremity TMR
when compared to studies reporting on lower extremity
TMR. However, early results in both upper and lower
extremities appear very promising.

Conclusion
These novel surgical techniques are revolutionizing the
thought processes and outcomes for prevention and management of amputation-related pain. TMR is an effective technique and represents a significant advance in the field of
amputation surgery. It should be considered by all surgeons
performing amputation surgery as it has the potential to prevent the development of both PLP and RLP. This technique
is gaining acceptance across a variety of amputation sites,
residual limb levels and indications. The benefits of TMR
are expected to impact many medical specialties.
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